patronestaff-shutterstock-com
patronestaff / Shutterstock.com
17 December 2015PharmaAshley Roughton

Divide and destroy: an overview of poisonous divisionals

A patent application can in effect destroy itself. It works like this: a priority filing might claim a kinase which has an acceptable homology with a particular sequence listing—call that kinase-SL. The filing which is eventually made claims the kinase as originally claimed and a more general description of it, such as any kinase which has general binding characteristics for a class of proteins, of which kinase-SL is a member—call that the class of kinases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
12 November 2026   Handing the pharma giant a major win in its feud with Pfizer and BioNTech, the UPC’s injunction reaches well beyond the court’s member states. But with an appeal still possible and parallel disputes playing out across the US and Europe, the fight is far from over.
Pharma
12 November 2026   From GLP-1 drugs to cancer treatments, counterfeiters are exploiting supply chain weaknesses and AI to evade detection. The US chamber’s director of IP tells LSIPR why the fight against fakes is becoming more complex and what lies ahead.
Pharma
10 November 2026   The pharma giant has filed a trademark and passing off claim in London to try and prevent UK consumers from accessing fake weight-loss drugs and other prescription medicines, after its rival’s success in a similar claim earlier in 2026.